40 research outputs found
On the Development and Management of Adaptive Business Collaborations.
Today’s business climate demands a high rate of change with which Information Technology (IT)-minded organizations are required to cope. Organizations face rapidly changing market conditions, new competitive pressures, new regulatory fiats that demand compliance, and new competitive threats. All of these situations and more drive the need for the IT infrastructure of an organization to respond quickly in support of new business models and requirements. This dissertation studies the adaptive development and management of such dynamic business models and requirements. A rule based environment is developed in which the people who develop and manage business collaborations in organizations can do so in a way that is as independent of specific implementation technologies as possible; and where they can take business requirements into consideration, and in which they can respond to changes as effectively as possible.
External Validation of Model-Based Dosing Guidelines for Vancomycin, Gentamicin, and Tobramycin in Critically Ill Neonates and Children: A Pragmatic Two-Center Study
Background: The Dutch Pediatric Formulary (DPF) increasingly bases its guidelines on model-based dosing simulations from pharmacokinetic studies. This resulted in nationwide dose changes for vancomycin, gentamicin, and tobramycin in 2015. Objective: We aimed to evaluate target attainment of these altered, model-based doses in critically ill neonates and children. Methods: This was a retrospective cohort study in neonatal intensive care unit (NICU) and pediatric ICU (PICU) patients receiving vancomycin, gentamicin, or tobramycin between January 2015 and March 2017 in two university hospitals. The first therapeutic drug monitoring concentration for each patient was collected, as was clinical and dosing information. Vancomycin and tobramycin target trough concentrations were 10–15 and ≤ 1 mg/L, respectively. Target gentamicin trough and peak concentrations were < 1 and 8–12 mg/L, respectively. Results: In total, 482 patients were included (vancomycin [PICU] n = 62, [NICU] n = 102; gentamicin [NICU] n = 97; tobramycin [NICU] n = 221). Overall, median trough concentrations were within the target range for all cohorts but showed large interindividual variability, causing nontarget attainment. Trough concentrations were outside the target range in 66.1%, 60.8%, 14.7%, and 23.1% of patients in these four cohorts, respectively. Gentamicin peak concentrations were outside the range in 69% of NICU patients (term neonates 87.1%, preterm infants 57.1%). Higher creatinine concentrations were associated with higher vancomycin and tobramycin trough concentrations. Conclusion: This study illustrates the need to validate model-based dosing advice in the real-world setting as both sub- and supratherapeutic concentrations of vancomycin, gentamicin, and tobramycin were very prevalent. Our data underline the necessity for further individualization by addressing the high interindividual variability to improve target attainment